|
1
|
Fenaux P, Haase D, Santini V, Sanz GF,
Platzbecker U and Mey U: Myelodysplastic syndromes: ESMO clinical
practice guidelines for diagnosis, treatment, and follow-up. Ann
Oncol. 32:142–156. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sekeres MA and Cutler C: How we treat
higher-risk myelodysplastic syndromes. Blood. 123:829–836. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aubrey BJ and Brunner AM: SOHO state of
the art and next questions: Treatment of higher-risk
myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 22:869–877.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Adès L, Itzykson R and Fenaux P:
Myelodysplastic syndromes. Lancet. 383:2239–2252. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Neukirchen J, Schoonen WM, Strupp C,
Gattermann N, Aul C, Haas R and Germing U: Incidence and prevalence
of myelodysplastic syndromes: Data from the Düsseldorf
MDS-registry. Leuk Res. 35:1591–1596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bewersdorf JP, Carraway H and Prebet T:
Emerging treatment options for patients with high-risk
myelodysplastic syndrome. Ther Adv Hematol.
11:20406207209550062020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fenaux P, Mufti GJ, Hellstrom-Lindberg E,
Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz
G, List A, et al: Efficacy of azacitidine compared with that of
conventional care regimens in the treatment of higher-risk
myelodysplastic syndromes: A randomised, open-label, phase III
study. Lancet Oncol. 10:223–232. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zeidan AM, Sekeres MA, Garcia-Manero G,
Steensma DP, Zell K, Barnard J, Ali NA, Zimmerman C, Roboz G,
DeZern A, et al: Comparison of risk stratification tools in
predicting outcomes of patients with higher-risk myelodysplastic
syndromes treated with azanucleosides. Leukemia. 30:649–657. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bernal T, Martínez-Camblor P,
Sánchez-García J, de Paz R, Luño E, Nomdedeu B, Ardanaz MT, Pedro
C, Amigo ML, Xicoy B, et al: Effectiveness of azacitidine in
unselected high-risk myelodysplastic syndromes: Results from the
Spanish registry. Leukemia. 29:1875–1881. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zeidan AM, Hu X, Zhu W, Stahl M, Wang R,
Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, et al:
Association of provider experience and clinical outcomes in
patients with myelodysplastic syndromes receiving hypomethylating
agents. Leuk Lymphoma. 61:397–408. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Greenberg PL, Tuechler H, Schanz J, Sanz
G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus
F, et al: Revised international prognostic scoring system for
myelodysplastic syndromes. Blood. 120:2454–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Greenberg P, Cox C, LeBeau MM, Fenaux P,
Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, et al:
International scoring system for evaluating prognosis in
myelodysplastic syndromes. Blood. 89:2079–2088. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kantarjian H, O'Brien S, Ravandi F, Cortes
J, Shan J, Bennett JM, List A, Fenaux P, Sanz G, Issa JP, et al:
Proposal for a new risk model in myelodysplastic syndrome that
accounts for events not considered in the original international
prognostic scoring system. Cancer. 113:1351–1361. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mozessohn L, Cheung MC, Fallahpour S, Gill
T, Maloul A, Zhang L, Lau O and Buckstein R: Azacitidine in the
‘real-world’: An evaluation of 1101 higher-risk myelodysplastic
syndrome/low blast count acute myeloid leukaemia patients in
Ontario, Canada. Br J Haematol. 181:803–815. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Diamantopoulos PT and Viniou NA: Factors
affecting response to 5-azacytidine and prognosis of
myelodysplastic syndrome. Is long-term survival a realistic goal?
Leuk Res. 103:1065432021.PubMed/NCBI
|
|
16
|
Diamantopoulos PT, Symeonidis A, Pappa V,
Kotsianidis I, Galanopoulos A, Pontikoglou C, Anagnostopoulos A,
Vassilopoulos G, Zikos P, Hatzimichael E, et al: The effect of
5-azacytidine treatment delays and dose reductions on the prognosis
of patients with myelodysplastic syndrome: How to optimize
treatment results and outcomes. Br J Haematol. 192:978–987. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Derissen EJB, Beijnen JH and Schellens
JHM: Concise drug review: Azacitidine and decitabine. Oncologist.
18:619–624. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Uchida T, Ogawa Y, Kobayashi Y, Ishikawa
T, Ohashi H, Hata T, Usui N, Taniwaki M, Ohnishi K, Akiyama H, et
al: Phase I and II study of azacitidine in Japanese patients with
myelodysplastic syndromes. Cancer Sci. 102:1680–1686. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van der Helm LH, Alhan C, Wijermans PW,
van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn
M, van Rees BP, de Weerdt O, et al: Platelet doubling after the
first azacitidine cycle is a promising predictor for response in
myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia
(CMML) and acute myeloid leukaemia (AML) patients in the Dutch
azacitidine compassionate named patient programme. Br J Haematol.
155:599–606. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu PF, Deng LN, Meng FK, Wang Y, Xiao M
and Li DJ: platelet doubling after first decitabine cycle predicts
response and survival of myelodysplastic syndrome patients. Curr
Med Sci. 42:77–84. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Radakovich N, Sallman DA, Buckstein R,
Brunner A, Dezern A, Mukerjee S, Komrokji R, Al-Ali N, Shreve J,
Rouphail Y, et al: A machine learning model of response to
hypomethylating agents in myelodysplastic syndromes. IScience.
25:1049312022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Arber DA, Orazi A, Hasserjian R, Thiele J,
Borowitz MJ, Beau MM, Bloomfield CD, Cazzola M and Vardiman JW: The
2016 revision to the World Health Organization classification of
myeloid neoplasms and acute leukemia. Blood. 127:2391–2405. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yonemura Y, Matsumoto M, Inada E, Ueda Y,
Ohishi K, Kubo T, Kumakawa M, Sueoka E, Sonoki T, Nagai K, et al:
Guideline for the use of red blood cell products based on
scientific evidence (Revision 2nd edition). Jpn J Transf Cell Ther.
64:688–699. 2018.(In Japanese).
|
|
24
|
Takami A, Matsushita T, Ogata M, Fujii N,
Kubuki Y, Fujiwara S, Matsumoto M and Tomiyama Y: Guideline for the
use of platelet transfusion concentrates based on scientific
evidence: Update 2019. Jpn J Transf Cell Ther. 65:544–561. 2019.(In
Japanese).
|
|
25
|
Schober P, Boer C and Schwarte LA:
Correlation coefficients: Appropriate use and interpretation.
Anesth Analg. 126:1763–1768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Harrell FE Jr, Califf RM, Pryor DB, Lee KL
and Rosati RA: Evaluating the yield of medical tests. JAMA.
247:2543–2546. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Harrell FE Jr, Lee KL and Mark DB:
Multivariable prognostic models: Issues in developing models,
evaluating assumptions and adequacy, and measuring and reducing
errors. Stat Med. 15:361–387. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Silverman LR, Fenaux P, Mufti GJ, Santini
V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD and
Seymour JF: Continued azacitidine therapy beyond time of first
response improves quality of response in patients with higher-risk
myelodysplastic syndromes. Cancer. 117:2697–2702. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gore SD, Fenaux P, Santini V, Bennett JM,
Silverman LR, Seymour JF, Hellström-Lindberg E, Swern AS, Beach CL
and List AF: A multivariate analysis of the relationship between
response and survival among patients with higher-risk
myelodysplastic syndromes treated within azacitidine or
conventional care regimens in the randomized AZA-001 trial.
Haematologica. 98:1067–1072. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Diamantopoulos PT, Pappa V, Symeonidis A,
Kotsianidis I, Galanopoulos A, Papadaki H, Anagnostopoulos A,
Vassilopoulos G, Zikos P, Hatzimichael E, et al: Characteristics of
Long-term survival in patients with myelodysplastic syndrome
treated with 5-Azacyditine: Results From the Hellenic 5-Azacytidine
registry. Clin Lymphoma Myeloma Leuk. 20:114–121. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Greenberg PL, Stone RM, Al-Kali A, Bennett
JM, Borate U, Brunner AM, Chai-Ho W, Curtin P, de Castro CM, Deeg
HJ and DeZem AE: NCCN Guidelines® Insights:
Myelodysplastic Syndromes, Version 3.2022. Featured Updates to the
NCCN Guidelines. J Natl Compr Canc Netw. 20:106–117. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Palacios-Berraquero ML and Alfonso-Piérola
A: Current therapy of the patients with MDS: Walking towards
personalized therapy. J Clin Med. 10:21072021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Laribi K, Bolle D, Alani M, Ghnaya H,
Besançon A, Farhi J, Mheidly K, Denizon N and de Materre AB: Impact
of the relative dose intensity on survival of patients with
high-risk myelodysplastic syndromes treated with Azacitidine.
Cancer Med. 8:2188–2195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Eladl E, Tremblay-LeMay R, Rastgoo N,
Musani R, Chen W, Liu A and Chang H: Role of CD47 in hematological
malignancies. J Hematol Oncol. 13:962020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zeidan AM, Komrokji RS and Brunner AM:
TIM-3 pathway dysregulation and targeting in cancer. Expert Rev
Anticancer Ther. 21:523–534. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bersanelli M, Travaglino E, Meggendorfer
M, Matteuzzi T, Sala C, Mosca E, Chiereghin C, Nanni ND, Gnocchi M,
Zampini M, et al: Classification and Personalized prognostic
assessment on the basis of clinical and genomic features in
Myelodysplastic Syndromes. J Clin Oncol. 39:1223–1233. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nazha A, Komrokji R, Meggendorfer M, Jia
X, Radakovich N, Shreve J, Hilton CB, Nagata Y, Hamilton BK,
Mukherjee S, et al: Personalized prediction model to risk stratify
patients with Myelodysplastic Syndromes. J Clin Oncol.
39:3737–3746. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu YC, Kwon J, Fabiani E, Xiao Z, Liu YV,
Follo MY, Liu J, Huang H, Gao C, Liu J, et al: Demethylation and
up-regulation of an oncogene after Hypomethylating therapy. N Engl
J Med. 386:1998–2010. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Papaemmanuil E, Gerstung M, Malcovati L,
Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC,
Pellagatti A, et al: Clinical and biological implications of driver
mutations in myelodysplastic syndromes. Blood. 122:3616–3627. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Haferlach T, Nagata Y, Grossmann V, Okuno
Y, Bacher U, Nagae G, Schnittger S, Sanada M, Kon A, Alpermann T,
et al: Landscape of genetic lesions in 944 patients with
myelodysplastic syndromes. Leukemia. 28:241–247. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bejar R, Stevenson K, Abdel-Wahab O,
Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine
RL, Neuberg D and Ebert BL: Clinical effect of point mutations in
myelodysplastic syndromes. N Engl J Med. 364:2496–2506. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoshida K, Sanada M, Shiraishi Y, Nowak D,
Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, et
al: Frequent pathway mutations of splicing machinery in
myelodysplasia. Nature. 478:64–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
